Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101094 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yoshihito Kogure und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan. Electronic address: yosh.kogure@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemetrexed, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center, MSD, Merck Sharp and Dohme K.K..
Abstract (Originalsprache)
BACKGROUND: The CJLSG1901 phase 2 study evaluated efficacy and safety of pembrolizumab plus pemetrexed in older populations. A novel first-line approach for older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) was assessed. METHODS: A subgroup analysis was conducted to determine the efficacy and safety of pembrolizumab plus pemetrexed in older patients with metastatic non-squamous NSCLC according to programmed cell death-ligand 1 (PD-L1) status (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan. Electronic address: yosh.kogure@gmail.com.
- Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
- Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan.
- Department of Respirology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Förderung
- National Cancer Center
- MSD
- Merck Sharp and Dohme K.K.
Zitieren
APA
Kogure, Y., Hashimoto, H., Ikeda, S., Harada, T., Hino, A., Miura, S., Goto, Y., Fujiwara, K., Katakami, N., Kubota, K., Murata, N., Mori, M., Abe, T., Saito, A. M., Yamamoto, N., Saka, H., & Kondo, M. (2026). Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101094
Vancouver
Kogure Y, Hashimoto H, Ikeda S, Harada T, Hino A, Miura S, et al. Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101094
BibTeX
@article{Kogure2026,
author = {Kogure, Yoshihito and Hashimoto, Hiroya and Ikeda, Satoshi and Harada, Toshiyuki and Hino, Aoi and Miura, Satoru and Goto, Yasuhiro and Fujiwara, Keiichi and Katakami, Nobuyuki and Kubota, Kaoru and Murata, Naohiko and Mori, Masahide and Abe, Takashi and Saito, Akiko M and Yamamoto, Nobuyuki and Saka, Hideo and Kondo, Masashi},
title = {Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101094}
}
EUVIMED